Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 8/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PAM | P19021 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27925026 | 0.81 | TDP1 (0.36) | ALDH1A1MAPTKMT2A | |
| SCHEMBL11100479 | 0.77 | EPHX1 (0.52) | ACHEALDH1A1EPHX1 | |
| SCHEMBL21059108 | 0.76 | EPHX1 (0.60) | ACHEEPHX1 | |
| Ammonia Solution, Strong SCHEMBL27626603 | 0.76 | EPHX1 (0.50) | ACHEALDH1A1EPHX1 | |
| SCHEMBL27983643 | 0.75 | EPHX1 (0.38) | ACHEALDH1A1EPHX1 | |
| SCHEMBL18989761 | 0.75 | TSHR (0.35) | ALDH1A1EPHX1MAPTKMT2A | |
| SCHEMBL9425078 | 0.74 | HSP90AA1 (0.48) | CES2CES1ALDH1A1HAO1EPHX1 | |
| SCHEMBL29173247 | 0.74 | ALDH1A1 (0.41) | CES2CES1ALDH1A1CA1PAM | |
| SCHEMBL21059244 | 0.74 | EPHX1 (0.63) | ACHEEPHX1 | |
| SCHEMBL28804144 | 0.74 | EPHX1 (0.63) | ACHEEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216787-A1 | THIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1721905-A1 | THIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216787-A1 | THIAZOLE DERIVATIVE | TGFBR1, TGFBR2, SMAD3 | CES2 3558/4885CES1 3615/4885ACHE 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.